Ryan Hunter, PhD, associate professor of microbiology and immunology, recently created a device to study anaerobic bacteria alongside oxygenated cells, simulating microenvironments within the body.

affecting nasal airflow, olfactory function, and quality of life. Epithelial barrier dysfunction and type 2 inflammatory responses drive disease progression. Treatments such as intranasal ...

Polyrizon anticipates completing the brand development process in alignment with its ongoing clinical and regulatory milestones.

Studies to assess efficacy, safety, user experience, and nasal residence time as Company prepares for regulatory path forward Raanana, Israel, March 27, 2025 (GLOBE NEWSWIRE) -- Polyrizon Ltd. (Nasdaq ...

Aegis Capital Corp. is acting as exclusive placement agent for the private placement. Greenberg Traurig, P.A. is acting as counsel to the Company. Kaufman & Canoles, P.C. is acting as counsel to Aegis ...

After Tezspire reduced the need for nasal polyp surgery by 98% in patients with a severe respiratory condition, the biopharma ...

Polyrizon Ltd. (Nasdaq: PLRZ) (the "Company" or "Polyrizon"), a development stage biotech company specializing in the development of innovative intranasal ...

Nasal polyp and congestion scores fell ... it really starts with disruption of the chronic epithelium,” Han said during his presentation. Patients with CRSwNP have elevated levels of thymic ...

Gut microbiota composition and sex hormones influence the immune response to methicillin-resistant Staphylococcus aureus gastrointestinal colonization in mice.